Work Here?
Overview
Spirair develops minimally invasive ENT medical devices. Its SeptAlign system uses a bioabsorbable implant to straighten minor nasal septal deviations in an in-office procedure under local anesthesia, with the implant dissolving in about six months after the cartilage holds its new shape. In 2025 it added TurbAlign to separate the middle turbinate from the nasal wall to aid healing after sinus surgery. The company sells these devices to ENT professionals and differentiates itself by tissue-preserving implants for office-based correction, aiming to improve nasal airway outcomes with less invasive options and shorter recovery.
About Spirair
Industries
Healthcare
Company Size
11-50
Company Stage
N/A
Total Funding
N/A
Headquarters
South San Francisco, California
Founded
N/A
Get referred to Spirair
See people who can refer or advise you
Simplify's Take
What believers are saying
- TurbAlign won FDA 510(k) clearance on July 11, 2025.
- Spirair posted Sr. R&D Engineer jobs in May and July 2026.
- SEC filings show $24.7 million sold in a $28.2 million offering.
What critics are saying
- Spirair reported no revenues in its March 2026 Form D amendment.
- ENT adoption can stall if surgeons prefer established septoplasty and sinus workflows.
- If reimbursement lags, Spirair burns cash before scaling, threatening company survival.
What makes Spirair unique
- SeptAlign became FDA-cleared in 2024 as a first minimally invasive NSD therapy.
- Bioabsorbable implants enable office-based ENT procedures under local anesthesia, not hospital septoplasty.
- TurbAlign extends Spirair into a broader, implant-based ENT product platform.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Paid Vacation
Growth & Insights and Company News
6 month growth
↑ 16%1 year growth
↑ 21%2 year growth
↑ 21%Spirair has filed a notice with the U.S. SEC for an exempt offering of securities to raise up to $23.6 million in new funding. This filing is required under federal securities law for companies selling securities without registration under the Securities Act of 1933, using exemptions like Rule 504 or 506 of Regulation D. The notice must be filed within 15 days of the first sale. Spirair specializes in minimally invasive solutions for ENT care.
Spirair is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Spirair
Industries
Healthcare
Company Size
11-50
Company Stage
N/A
Total Funding
N/A
Headquarters
South San Francisco, California
Founded
N/A
Spirair is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today